Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07781371 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Retrospective Real-World Cohort Study

Study acronym: SCALA-TK-CM
StatusNot Yet Recruiting
PhaseNot specified
Started2026-08-20
View on ClinicalTrials.gov ↗
The primary objectives are to determine the prevalence and overlap of major cardiometabolic diseases, identify multimorbidity clusters, and characterize demographic, clinical, laboratory, and treatment patterns across the cohort and relevant subgroups. This study is based on anonymized electronic health record (EHR) data and spanning January 2022 to December 2025. EHR will be extracted from participants of Acibadem hospital network in Turkey. Participants received routine clinical care according to physician discretion. Index date will be defined by the first diagnosis of cardiometabolic conditions. Follow-up period will include at least one year of to allow description of long-term outcomes. It will extend until the end of study, last recorded encounter, or death.
Trial Details
NCT Number NCT07781371
Lead Sponsor Novo Nordisk A/S
Conditions Obesity, Type 2 Diabetes (T2D), Prediabetes, Cardiovascular Disease (CVD), Dyslipidemia, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Chronic Kidney Disease (CKD)
Enrollment 100,000 participants
Start Date 2026-08-20
Primary Completion 2026-11-02 (estimated)
Study Completion 2026-11-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-24